Gilead Sciences (NASDAQ:GILD) CFO Sells $366,000.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the sale, the chief financial officer owned 153,503 shares of the company’s stock, valued at approximately $18,727,366. This represents a 1.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Gilead Sciences Stock Performance

GILD traded down $1.00 on Tuesday, reaching $118.78. The company had a trading volume of 6,211,164 shares, compared to its average volume of 7,887,689. The stock has a market cap of $147.37 billion, a P/E ratio of 18.42, a P/E/G ratio of 0.67 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The company’s fifty day moving average is $122.02 and its 200 day moving average is $115.87.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the company posted $2.02 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Institutional Investors Weigh In On Gilead Sciences

A number of large investors have recently bought and sold shares of the company. Activest Wealth Management boosted its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at $27,000. Finally, Putney Financial Group LLC increased its stake in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. Scotiabank initiated coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective on the stock. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. HSBC increased their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Finally, Argus raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $131.54.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.